RxDoctor Payments Data

Bernard Zeffren, MD

Allergy & Immunology · Daytona Beach, FLNPI 1982609046

Payments from drug & device makers

$6,440in general payments, 2019–2025

Across 243 payments — averaging $26.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • Regeneron Healthcare Solutions, Inc.$846
  • GSK$669
  • Novartis$538
  • Takeda Pharmaceuticals U.S.A., Inc.$496
  • CSL Behring$353
  • plus $2K from 17 others

What the payments were for

  • Food & beverage$6,425100%
  • Education$150%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,440 in reported general payments places this provider in the 50th percentile of 204 allergy & immunology providers in Florida.

See all allergy & immunology providers in Florida

Medicare billing

Part B allowed, 2024
$555,992
Medicare patients
661
Services billed
22,175

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter83$76,002
Breo ElliptaFluticasone/Vilanterol60$27,627
Arnuity ElliptaFluticasone Furoate50$14,407
SymbicortBudesonide/Formoterol Fumarate22$8,220
Ipratropium Bromide100$2,639
Azelastine Hcl87$2,405
Epinephrine11$2,389
Fluticasone Propionate129$2,013
Mometasone Furoate15$1,521
Fluticasone-SalmeterolFluticasone Propion/Salmeterol16$1,246
Albuterol Sulfate HfaAlbuterol Sulfate25$732
Betamethasone Dipropionate13$641
Triamcinolone Acetonide19$284
Montelukast Sodium33$267
Omeprazole19$141

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta$669$118,036193 claims
AstraZenecaSymbicort$1,301$8,22022 claims
Hikma Pharmaceuticals USAEpinephrine$17$2,38911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 204 allergy & immunology providers in Florida.

Other allergy & immunology in Daytona Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →